Gland Pharma Ltd.

•

glandpharma.comBSE: 543245NSE: GLAND

Market Cap₹ 48,215 Cr.

Current Price

High / Low₹ 3,042 / 1,574

Stock P/E42.7

Book Value₹ 644

Price to Book2.71

Dividend Yield0.68 %

ROCE15.0 %

ROE10.6 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Company has consistently been profitable over the last 5 years
Latest quarter profit grew 47.1% YoY, showing strong momentum
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.18x)
Company has been maintaining a healthy dividend payout of 32.1%

CONS

Company has a low return on equity of 9.2% over last 3 years
Company has delivered a poor profit growth of 0.6% over past five years
Operating margins have contracted to 25.3% from 34.9%
Expensive relative to growth - PEG of 4.5

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY PHARMA NIFTY MNC NIFTY TOTAL MKT NIFTY SMLCAP 50 NIFTY 500

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	GLAND	2922.70	42.71	48214.81	0.68	316.96	47.09	1800.27	19.57	14.96	27.18

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,209	1,373	1,545	1,537	1,402	1,406	1,384	1,425	1,506	1,487	1,695	1,743	1,800
	915	1,049	1,189	1,179	1,137	1,109	1,024	1,077	1,138	1,173	1,260	1,230	1,427
Operating Profit	294	324	356	359	264	297	360	348	368	314	435	513	374
OPM %	24.32%	23.60%	23.06%	23.33%	18.86%	21.13%	26.01%	24.39%	24.43%	21.11%	25.65%	29.44%	20.76%
	38	53	37	42	51	60	58	44	58	84	39	111	61
Interest	5	6	5	10	6	6	23	7	12	8	4	10	4
Depreciation	65	81	105	93	92	94	96	96	101	106	108	109	111
Profit before Tax	261	290	283	298	218	257	299	288	313	284	362	506	435
Tax %	25.71%	33.05%	32.24%	35.48%	34.13%	36.32%	31.61%	35.30%	31.10%	35.30%	27.79%	27.50%	27.13%
Net Profit	0	0	0	0	144	164	205	187	215	184	261	367	317
	11.79	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.26	19.23

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,633	3,463	4,401	3,625	5,665	5,617	6,431	6,725
	1,678	2,161	2,891	2,600	4,332	4,348	4,801	5,090
Operating Profit	955	1,302	1,510	1,025	1,333	1,269	1,630	1,636
OPM %	36.28%	37.61%	34.32%	28.27%	23.53%	22.59%	25.34%	24.32%
	139	135	224	184	170	214	292	296
Interest	7	3	5	7	26	42	33	26
Depreciation	95	99	110	147	345	378	424	434
Profit before Tax	993	1,335	1,619	1,055	1,133	1,063	1,465	1,587
Tax %	22.16%	25.31%	25.14%	25.94%	31.79%	34.27%	29.86%	28.86%
Net Profit	773	997	1,212	781	772	699	1,027	1,129
EPS	49.88	62.99	73.54	47.43	46.90	42.40	62.35	—
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	42.65%	42.46%	32.08%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: 13%
3 Years:: 21%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: 1%
3 Years:: 10%

STOCK PRICE CAGR

10 Years:: —
5 Years:: -6%
3 Years:: 21%
1 Year:: 49%

RETURN ON EQUITY

10 Years:: —
5 Years:: 11%
3 Years:: 9%
Last Year:: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15	16	16	16	16	16	16
	3,614	5,861	7,128	7,941	8,706	9,134	10,296
	7	6	6	5	182	149	134
Trade Payables	249	396	463	587	768	820	834
	200	215	220	228	939	1,053	1,168
Total Liabilities	4,086	6,496	7,834	8,778	10,611	11,173	12,449
	968	954	1,502	1,571	3,947	4,147	4,492
Capital Work in Progress	188	338	181	177	238	151	342
	0	0	155	0	0	0	0
	756	1,275	1,186	1,945	1,655	1,685	1,744
	0	0	0	0	1,559	1,517	1,891
Cash & Bank	1,325	3,006	3,093	3,771	1,839	2,556	3,359
	848	923	1,717	1,314	1,373	1,117	620
Total Assets	4,086	6,496	7,834	8,778	10,611	11,173	12,449

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	945	916	1,197	675	997	915	1,031
Cash from Investing	-766	-1,524	-1,003	1,208	-1,757	1,705	138
Cash from Financing	-7	1,238	35	15	-799	-433	-417
	-72	319	-177	1,587	-1,560	2,186	752

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.77
	6.88	4.48	5.04	6.90	7.39	7.90	7.58	7.29	8.74
	32.83	35.37	34.80	33.27	32.86	32.63	32.99	33.36	30.44
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	8.45	8.32	8.33	7.99	7.93	7.63	7.61	7.52	9.05

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-10 - Gland Pharma Limited has informed the Exchange about Schedule of meet

2026-09-08

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-08 - Gland Pharma Limited has informed the Exchange about Schedule of meet

2026-09-04

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-04 - Gland Pharma Limited has informed the Exchange about Schedule of meet

2026-09-01

General Updates

2026-09-01 - Gland Pharma Limited has informed the Exchange about General Updates

2026-08-31

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-31 - Gland Pharma Limited has informed the Exchange about Schedule of meet

2026-08-26

Shareholders meeting

2026-08-26 - Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 25, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-25

Shareholders meeting

2026-08-25 - Gland Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026

2026-08-23

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-23 - Gland Pharma Limited has informed the Exchange about Schedule of meet

2026-08-17

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-17 - Gland Pharma Limited has informed the Exchange about Transcript

News

Recent coverage and analyst commentary for GLAND

Loading news…

🤖

AI Stock Analyst

Gland Pharma Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account